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Hyperglycemia has detrimental effects on normal organ
functions in people with diabetes, chieﬂy contributing to the
development of diabetic complications in both central and
peripheral organs (1). Hyperglycemia, a hallmark of diabe-
tes, results from dysregulation of both glucose intake/
production and uptake/utilization. In type 1 diabetes, due
to pancreatic b-cell death and insulin deﬁciency, glucose
uptake and disposal decrease signiﬁcantly while endogenous
glucose production increases. In type 2 diabetes, due to insulin
resistance and impaired insulin secretion, glucose homeosta-
sis is similarly dysregulated. With regard to the endogenous
glucose production, there are two metabolic processes—
gluconeogenesis and glycogenolysis. The liver is the major
organ responsible for both processes (2). Thus, the control
of hepatic glucose production is highly relevant to the treat-
ment of both type 1 and type 2 diabetes.
Hepatic gluconeogenesis is regulated at multiple levels,
including expression of key gluconeogenic genes, enzymatic
activity, and substrate ﬂux. Phosphoenolpyruvate carboxyl-
ase (PEPCK) and glucose-6-phosphatase (G6Pase) are two
of the key enzymes that are involved in gluconeogenesis.
Expression of these two genes is reciprocally controlled by
insulin and glucagon (3). Upon insulin binding to insulin
receptor (IR), the IR is activated and initiates the insulin
signaling cascade through insulin receptor substrates (IRS),
phosphoinositide 3-kinase (PI3K), 3-phosphoinositide–
dependent protein kinase 1 (PDK1), and AKT/PKB kinase
(4). Multiple metabolic processes are regulated by the AKT
kinases, including gluconeogenesis and synthesis of glyco-
gen, lipid, and protein (5). Forkhead box O transcription
factors (FoxOs) are key regulators for hepatic gluconeo-
genesis (6–8). There are four FoxO genes in mammals—
FoxO1/3/4/6 (9). The transcriptional activity of FoxOs is
tightly controlled by protein phosphorylation and dephos-
phorylation. AKT is a major kinase that potently inhibits
the activity of FoxOs by phosphorylating the well-conserved
sites in FoxOs: FoxO1-T24/S256/S319, FoxO3-T32/S253/
S315, FoxO4-T32/S197/S262, and FoxO6-T26/S184 (5).
Upon phosphorylation of FoxOs by AKT, the phosphory-
lated FoxOs can bind 14-3-3 adaptor proteins and are sub-
sequently translocated to the cytoplasm (10).
In contrast to abundant studies of kinases for FoxOs,
much less is known about phosphatases for this group of
transcription factors. Protein phosphatase 2A (PP2A) and
dual speciﬁcity phosphatase 6/mitogen-activated protein
kinase phosphatase 3 (DUSP6/MKP3) have been implicated
in the dephosphorylation of FoxO1 in the cytosol (11,12).
However, it is unclear whether PP2A or MKP3 plays a sig-
niﬁcant role in the dephosphorylation of FoxOs in the nu-
cleus. In this issue of Diabetes, Cao et al. (13) identiﬁed a
new FoxO1/3a phosphatase—CTD (C-terminal domain of
RNA polymerase II) small phosphatase-like 2 (CTDSPL2),
also known as small CTD phosphatase 4 (SCP4)—in the
nucleus. This is a signiﬁcant advancement of our under-
standing of the activation of the FoxO transcription by a
nuclear phosphatase. This study was initiated from a
screen of a 40-member phosphatase library using FoxO1
and FoxO3a as substrates. SCP4 turned out to be a top
hit. Serial in vitro and in vivo experiments veriﬁed that
FoxO1/3a are bona ﬁde substrates of SCP4, including in
vitro dephosphorylation assays using puriﬁed enzymes, sub-
strates, and phosphatase-inactive mutants. Interestingly,
FoxO1–p-Ser256 and FoxO3a–p-Ser253 are preferred dephos-
phorylation sites by SCP4. As expected, SCP4 modulates
subcellular localization of FoxO1/3a according to their phos-
phorylation status. Overexpression of wild-type SCP4 but not
phosphatase-inactive mutants increases nuclear localization
of FoxO1/3a. Furthermore, SCP4 enhances the transcrip-
tional activity of FoxOs, with a focus on regulation of the
PEPCK and G6PC genes and hepatic glucose production.
The physiological data from the SCP4-deﬁcient mice (cre-
ated by gene trap) have provided strong evidence to support
the role of SCP4 in glucose homeostasis as the SCP4-
deﬁcient pups die within 24 h after birth due to hypogly-
cemia. Glucose supplementation extends the life span of
the mutant pups by about 20 h. At molecular levels, SCP4
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deﬁciency elevates FoxO phosphorylation and decreases
expression of the PEPCK and G6PC genes in the livers of
SCP4 mutant mice. Interestingly, starvation induces the
SCP4 gene in mouse liver, revealing a connection to the
starvation process of which gluconeogenesis is a part.
Identiﬁcation of SCP4 as a key regulator of FoxOs in
hepatic gluconeogenesis advances our understanding of
glucose homeostasis. The study by Cao et al. (13) elegantly
demonstrates the biochemical nature of the SCP4-FoxO1/3a
interaction as phosphatase and substrates. The cellular and
mouse data also support a strong role of SCP4 in hepatic
gluconeogenesis. The neonatal lethality in the SCP4-
deﬁcient mice is very striking. Nevertheless, some cautions
should be exercised when one interprets the ﬁndings
from this work. First, as the SCP4 mutant mice are system-
ically deﬁcient in SCP4, the lethality phenotype cannot be
solely attributed to hepatic gluconeogenesis and the SCP4
function in other metabolically critical organs should be
examined and characterized. Previously, it has been shown
that SCP4 is also involved in globin gene expression, CTD-
Ser5 dephosphorylation, bone morphogenetic protein
signaling and mesenchymal differentiation, and muscle
wasting in chronic kidney disease (14–17). Moreover, a
conditional knockout animal model is needed to character-
ize the tissue-speciﬁc function of SCP4. Second, as glucose
homeostasis is a balance between input (intake and syn-
thesis) and output (utilization and storage), in addition to
gluconeogenesis examined in the current study, glucose up-
take, glycolysis, glycogenolysis, and citric acid cycle in the
liver, skeletal muscle, adipose tissue, and brain should be
analyzed as well. It is known that FoxOs also suppress expres-
sion of glycolytic genes, including glucokinase and pyruvate
kinase (18,19). Third, it is rather surprising that autophagy
is not changed in the liver of SCP4-deﬁcient mice. It has
been previously reported that FoxOs induce a number of
autophagy-related genes (ATG), including ATG5, ATG14, and
MAP1LC3B (20). An alternative assay such as autophagy
ﬂux might be used to validate the ﬁnding. Last, whether
SCP4 impacts other known FoxO phosphatases, such as PP2A
and MKP3, should be addressed in a future study as well.
In summary, identiﬁcation of SCP4 as a key nuclear
phosphatase for FoxO transcription factors should help us
better understand the dynamics of checks and balances of
these critical mediators in the insulin signaling pathway
Figure 1—Regulation of the FoxO1/3 activity by phosphorylation. FoxO transcription factors, including FoxO1/3, are tightly regulated by
phosphorylation and dephosphorylation events. Upon insulin stimulation, AKT is activated by the upstream signaling pathway IR → IRS →
PI3K→ PDK1/mTORC2. The activated AKT kinase regulates numerous target proteins including FoxO1 and FoxO3a through phosphorylation.
The Akt phosphorylation of FoxOs, especially at Ser256 (FoxO1) and Ser253 (FoxO3a), is inhibitory. Phosphorylated FoxOs are subject to binding
with 14-3-3 scaffold proteins and nuclear exclusion. When SCP4 has access to phosphorylated FoxO1/3a (Ser256/Ser253) that are not bound by
14-3-3, FoxO1/3a can be dephosphorylated and reactivated in the nucleus. As a result, hepatic gluconeogenic genes, including PEPCK and
G6PC, are induced. It is also expected that other FoxO-regulated processes are activated by SCP4 as well.
24 Commentary Diabetes Volume 67, January 2018
(Fig. 1). Whether SCP4 can be used as a drug target for
diabetes therapeutics awaits comprehensive understanding
of the role of SCP4 in pathophysiology. Is the expression or
activity of SCP4 changed in metabolically active tissues like
liver, skeletal muscle, adipose tissue, and pancreatic islets?
Will inhibition or knockdown of SCP4 improve hyperglyce-
mia or diabetes as a whole? How does SCP4 regulate lipid
homeostasis? Detailed characterization of relevant animal
models and molecular proﬁling of the SCP4 interactome
should provide much needed insights into the potential of
targeting SCP4 for diabetes treatment.
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